Compare Incyte Corporation (INCY) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Kingsoft Cloud Holdings Limited — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Kingsoft Cloud Holdings Limited trades at $10 (market cap $3.01B). The key difference: Incyte Corporation is far larger — about 7.7× Kingsoft Cloud Holdings Limited's market cap, and Incyte Corporation is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals.
| INCY | KC | |
|---|---|---|
Market Cap | $23.11B | $3.01B |
Sector | Health | Technology |
52-Week High | $118.52 | $18.21 |
52-Week Low | $67.38 | $8.58 |
Enterprise Value | $19.13B | $3.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Kingsoft Cloud (KC) trades at $10.04, up 5.24% today, showing strong momentum despite a bearish technical signal. The company reported Q1 2026 revenue growth of 37% year-over-year, driven by AI cloud demand, though profitability remains challenged with a -9.39% net margin. Analyst sentiment is positive with 70% buy ratings, citing potential from AI expansion and trade easing between the U.S. and China.
KC presents a growth opportunity in cloud and AI services with strong revenue acceleration, but investors face risks from persistent losses, high capital expenditure, and competitive pressures. The stock's outlook hinges on margin improvement from AI investments and sustained demand, making it suitable for growth-oriented investors tolerant of near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
